Pancreatic Cancer Trial, Recruiting NCT02869802 Sponsor: British Columbia Cancer Agency Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT02869802
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with pancreatic ductal adenocarcinoma (a type of pancreatic cancer) that has spread to other parts of the body, confirmed by tissue sample and/or imaging scans — those without a tissue-confirmed diagnosis must have a biopsy done before starting treatment
  • People who are planned to receive one of two specific chemotherapy combinations (called FOLFIRINOX or gemcitabine plus nab-paclitaxel) as their first treatment, either as standard care or as part of another clinical trial
  • People aged 18 or older
  • People who are generally well enough to carry out daily activities with little or no limitation, as measured by a standard medical fitness scale (ECOG score of 0 or 1)
  • People whose heart, liver, kidneys, and other organs are working well enough (confirm with trial site)
  • People whose doctor estimates they have a life expectancy of more than 90 days
  • People who are able to understand and agree to participate in the study
  • People who have at least one tumour that can be measured on a scan using standard criteria
  • People who have a tumour that a specialist radiologist considers safe to take a needle biopsy from, with at least 3 tissue samples safely obtainable using CT or ultrasound guidance
  • People who are well enough to safely undergo a tumour biopsy, as assessed by the trial doctor
  • People who are able to lie flat on their back for more than 60 minutes
  • (For a specific group in this trial) People who have a previously collected tumour tissue sample available, from either a past biopsy or surgical removal of the tumour

Who may not be able to join:

  • People whose cancer has not spread to distant parts of the body or lymph nodes — those with borderline or locally advanced pancreatic cancer that has not spread are not eligible
  • People who have already received chemotherapy or any other cancer treatment for advanced or metastatic disease (though people who had chemotherapy after surgery for early-stage disease may still be eligible)
  • People who are currently receiving any cancer treatment
  • People who the trial doctor considers not well enough to safely receive combination chemotherapy
  • People who have cancer that has spread to the brain
  • People who are pregnant (a positive pregnancy test is an exclusion)
  • People who the trial doctor considers unsafe to include in the study for any medical or personal reason
  • People who would not be able to attend study visits or complete follow-up requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Daniel J Renouf, MD, BC Cancer

Phone: 800-663-3333

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
British Columbia Cancer Agency
Registry
ClinicalTrials.gov
Start date
6 October 2016
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Number of days between biopsy and return of comprehensive genomic results.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov